| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CD-1530 | CTRPv2 | pan-cancer | AAC | 0.023 | 0.6 |
| mRNA | BMS-270394 | CTRPv2 | pan-cancer | AAC | -0.022 | 0.6 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | -0.022 | 0.6 |
| mRNA | Cisplatin | GDSC1000 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | -0.031 | 0.6 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | 0.02 | 0.6 |
| mRNA | STF-62247 | GDSC1000 | pan-cancer | AAC | 0.02 | 0.6 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.028 | 0.6 |
| mRNA | Ko-143 | CTRPv2 | pan-cancer | AAC | 0.022 | 0.6 |
| mRNA | SB 216763 | GDSC1000 | pan-cancer | AAC | 0.023 | 0.6 |